Damora Therapeutics (DMRA) Q3 2026 earnings summary

Executive summary

• Q3 2026 operating loss was $36.9M and net loss was $32.0M; cash, cash equivalents and marketable securities totaled $528.5M at quarter-end.

• DMR-001 entered Phase 1/1b CLARITY-101 testing in mutCALR-driven ET and MF; enrollment is ongoing, with FDA clearance for U.S. trial initiation.

• DMR-001 preclinical results showed 95-fold average improvement in anti-proliferative potency versus a reference antibody across 10 non-Type 1 CALR mutations, including Type 2.

Financial highlights

• Q3 R&D was $25.5M vs. $1.4M YoY; G&A was $11.4M vs. $1.7M; total operating expenses were $36.9M vs. $3.2M.

• Q3 net loss was $32.0M vs. $3.1M YoY; nine-month net loss was $90.9M vs. $9.1M. No product sales revenue has been generated.

• Nine-month R&D was $74.8M vs. $3.6M YoY; G&A was $27.9M vs. $5.6M. R&D included $11.9M of Paramora warrant compensation expense.

• Q3 other income, net was $4.9M, including $4.2M interest income and a $0.8M IP-sale gain; nine-month other income was $12.0M.

• Net cash used in operating activities was $17.2M in Q3 2026.

Outlook and guidance

• Existing cash, cash equivalents and marketable securities of $528.5M are expected to fund operations into 2H 2029; estimates depend on assumptions that may prove incorrect.

• First regulatory submission for DMR-002 is planned in Q4 2026 and for DMR-003 in 2027; additional DMR-001 regional applications are planned by year-end 2026.

• DMR-001 proof-of-concept datasets are expected beginning mid-2027; expansion cohorts are planned for 2027, and Phase 3 development could begin as early as mid-2028, subject to trial results.

• New DMR-001 preclinical data are planned for presentation at the ASH Annual Meeting in December 2026.

• R&D and G&A expenses are expected to rise substantially as programs advance, trials expand and infrastructure and headcount grow.